Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Alvaro J. AlencarRaquel MalumbresGoldi A. KozloskiRanjana H. AdvaniNeha TalrejaShideh ChinichianJavier BrionesYasodha NatkunamLaurie H. SehnRandy D. GascoyneRob TibshiraniIzidore S. Lossos
0
Citation
0
Reference
10
Related Paper
Abstract:
Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOPControversy has recently arisen as to whether diffuse intermediate lymphocytic lymphoma (ILL) should be considered a low-grade or an intermediate-grade non-Hodgkin's lymphoma for clinical purposes. Therefore, the authors performed a clinicopathologic study to determine the biologic course of diffuse ILL (40 cases) and compared it with small lymphocytic lymphoma (SLL; 51 cases) and diffuse small cleaved cell lymphoma (DSCCL; 14 cases). They found that patients with diffuse ILL having pseudofollicular proliferation centers (PC) had a significantly longer median survival (84 months) than those without PC (46.5 months; P = 0.03). The median survival of patients with SLL was 72 months, whereas those with DSCCL had a median survival of only 18 months. Based on these findings, the authors conclude that diffuse ILL with PC should be included in the low-grade category of SLL for clinical purposes, whereas diffuse ILL without PC (true diffuse ILL) should be considered an intermediate-grade non-Hodgkin's lymphoma. True diffuse ILL is similar to centrocytic lymphoma in the Kiel classification and should be accorded a similar status in a modified Working Formulation.
Cite
Citations (44)
Cutaneous diffuse large B-cell lymphoma, leg type, is a malignant lymphoma of intermediate behavior, occurring mostly on leg(s) of elderly patients. This chapter describes the clinical features, histopathology, immunophenotype, molecular genetics, treatment and prognosis of diffuse large B-cell lymphoma, leg type. It is a matter of discussion whether diffuse large B-cell lymphoma, leg type, is a specific entity per se, or does simply represent a primary cutaneous variant of diffuse large B-cell lymphoma, unspecified. In fact, there are more similarities than differences between these groups, and it has been suggested that diffuse large B-cell lymphoma, leg type, should not be considered as a separate entity, but rather classified within the group of diffuse large B-cell lymphoma, unspecified. It must be remembered that diagnosis of cutaneous diffuse large B-cell lymphoma, leg type, is made only upon negative staging investigations, as any extracutaneous diffuse large B-cell lymphoma may involve the skin secondarily.
Immunophenotyping
Histopathology
Cutaneous lymphoma
Large cell
Cite
Citations (0)
Read the full review for this Faculty Opinions recommended article: Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Cite
Citations (0)
Supplementary Figure Legends 1-2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Cite
Citations (5)
Objective To investigate and analyse rituximab combination with CHOP in patients with diffuse large B-cell lymphoma clinical effect. Method Select 86 cases of diffuse large B-cell lymphoma patients treatment in our hospital,randomly divided into two groups,which given rituximab with CHOP regimen combined treatment of 49 patients for the experimental group,and the remaining 37 cases only pure CHOP chemotherapy patients as the control group,the two groups of patients received six courses of treatment, the clinical effect of the two groups were compared. Results The control group efficiency was 86.49%,the experimental group efficiency of 93.88%,significantly higher than the control group(P 0.05). Conclusion Rituximab and CHOP regimen combined treatment of diffuse large B-cell lymphoma significant clinical effect,it is worth further promote in the use of clinical.
Regimen
Cite
Citations (0)
Cite
Citations (0)
Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Cite
Citations (0)